Role of FKBP52 in androgen signaling and hypospadias

Project: Research project

Description

DESCRIPTION (provided by applicant): Hypospadias is a common birth defect. Although its etiology is unknown, it is generally considered to arise from androgen insensitivity. In 1997, the Center for Disease Control and Prevention (CDC) released reports documenting an increase of almost 100% in hypospadias cases in the US from 1968 to 1993. It was suggested that environmental contamination by endocrine disrupting agents might have contributed to this outbreak. In spite of its high prevalence, mutations in androgen receptor (AR) or 5D-reductase have been found in less than 2% of the hypospadias patient population, suggesting that multiple targets in the pathways of androgen signaling or metabolism contribute to hypospadias. Surgical repair is the only treatment for hypospadias. Lack of an animal model for hypospadias has limited our efforts to identify the pathogenesis of the disease, as well as development of new therapies. In this application, we will investigate our discovery that the FK506-binding protein, FKBP52, is involved in the etiology of hypospadias. FKBP52 is also known as a steroid receptor associated-tetratricorpeptide repeat domain protein (SRA-TPR) based on its ability to enter into heterocomplexes with steroid receptors via a direct interaction with heat shock protein 90 (Hsp90). FKBP52 is one of several SRA-TPRs and is found in the AR complex, as well as in progesterone receptor (PR) and glucocorticoid receptor (GR) complexes. In the GR system, FKBP52 is known to increase the binding affinity for hormone, while FKBP51 (a closely-related SRA-TPR) serves to attenuate (but not abolish) this function. In an effort to study the role of FKBP52 in vivo, we generated FKBP52-deficient mice. Strikingly, FKBP52-deficient males give rise to severe hypospadias with 100% penetrance. Our initial morphological and histological characterization at both embryonic and adult stages revealed an essential role of FKBP52 in androgen-mediated male genital development. Accordingly, this proposal will test the hypothesis that FKBP52 is a key regulator of ligand-induced androgen receptor action and is critical to male urethral and genital development. We will test this hypothesis in the following ways: 1) we will determine the developmental mechanism of ventral urethral epithelium closure and male genital development; 2) we will determine the role of FKBP52 in androgen receptor signaling at both the cellular and molecular level; 3) we will study the contribution of FKBP51 to AR function and the development of hypospadias using mouse genetic tools.
StatusFinished
Effective start/end date2/1/0612/31/10

Funding

  • National Institutes of Health: $255,352.00
  • National Institutes of Health: $260,563.00
  • National Institutes of Health: $255,352.00
  • National Institutes of Health: $281,220.00

Fingerprint

Hypospadias
Androgens
Androgen Receptors
Steroid Receptors
Glucocorticoid Receptors
HSP90 Heat-Shock Proteins
tacrolimus binding protein 4
Penetrance
Progesterone Receptors
Centers for Disease Control and Prevention (U.S.)
Disease Outbreaks
Oxidoreductases
Epithelium
Hormones
Ligands
Tacrolimus Binding Proteins
Mutation
Tacrolimus

ASJC

  • Medicine(all)